JLE

European Cytokine Network

MENU

Benefits of granulocyte-colony-stimulating factor after stem cell transfusion in intensive sequential chemotherapy for breast cancer Volume 9, numéro 1, March 1998

Auteurs

INTRODUCTION Dose intensification in chemotherapy is commonly used, based on encouraging results seen during the treatment of several of chemosensitive tumors such as malignant lymphomas [1-4], poor-risk breast cancers [5] and advanced stages of ovarian carcinomas [6, 7]. Chemotherapy dose intensification is supported by recombinant hematopoietic growth factors (HGFs), such as filgrastim (r-metHuG-CSF), alone or in combination [...]